DIAGNOS Announces Contract With Dr. Vishal Gupta's Diabetes and Endocrine Clinic in Mumbai

BROSSARD, QUEBEC--(Marketwired - Sept. 9, 2014) - Diagnos Healthcare India Pvt. Ltd. ("DIAGNOS" or "the Corporation") (TSX VENTURE:ADK), a leader in healthcare technical services including screening, software and algorithm development, data analysis, and image processing, announced today the signing of a contract with Dr. Vishal Gupta's Diabetes and Endocrine Clinic in Mumbai for one retinopathy screening unit.

The clinic offers multiple services to people suffering from diabetes, including, but not limited to, diabetes risk assessment, consultation with an endocrinologist, consultation with a dietician, and diabetes education. India has a population of 1.24 billion people and, according to the International Diabetes Federation, has a diabetic population of 65 million.

"After establishing an Indian subsidiary less than a year ago, DIAGNOS is beginning to pick up steam in the region. We used the acquisition of a large client in India in 2013 as an opportunity to create a local presence, and, in the past year, we have opened an office in Mumbai, hired local staff, and begun developing local business relationships. This project with Vishal Gupta's Clinic is the first of many of these relationships that we expect to come to fruition," said André Larente, Diagnos' President.

About DIAGNOS

Founded in 1998, DIAGNOS is a publicly traded Canadian corporation, with a mission to commercialize technologies to improving decision making processes in different sectors. DIAGNOS offers products, services, and solutions to clients in a variety of fields including healthcare and natural resources.

About DIAGNOS Healthcare India Pvt. Ltd.

DIAGNOS Healthcare India Pvt. Ltd. is a business division with DIAGNOS Inc., achieving international recognition as leader in healthcare technical services including, screening, software and algorithm development, data analysis, and image processing. Through its Indian Healthcare division, DIAGNOS offers turn-key diabetic retinopathy screening services to patients in India.

Diabetic retinopathy is the most common diabetic eye disease and a leading cause of blindness around the world. It is a treatable disease that, as with most diseases, has a higher treatment success rate in its earlier stages. However, there are generally no symptoms until the disease has progressed to more severe stages, making early detection critical to helping prevent vision loss.

Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

For further information on DIAGNOS, please visit our website at www.diagnos.com or the SEDAR website at www.sedar.com.